Healthy Extracts (HYEX) AI Stock Analysis

• Market Cap: $33.74M
• Dividend Yield: N/A
• Average Volume (3M): 1.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: 19.20%
• EPS Growth: -19.98%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.06
• Shares Outstanding: 16,870,869
• 10 Day Avg. Volume: 902
• 30 Day Avg. Volume: 1,290
• PEG Ratio: 0.13
• Price to Book (P/B): 18.22
• Price to Sales (P/S): 2.40
• P/FCF Ratio: 26.51
• Enterprise Value/Market Cap: 0.17
• Enterprise Value/Revenue: 1.63
• Enterprise Value/Gross Profit: 3.11
• Enterprise Value/Ebitda: -7.32
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $2.00 ▲(1.52% Upside)

The score is held down primarily by weak financial performance: despite a sharp revenue rebound and improved gross margin, HYEX remains unprofitable and has returned to TTM cash burn, with leverage/solvency assessment constrained by incomplete TTM balance-sheet fields. Technicals are mildly supportive with price above key moving averages and a positive MACD, but valuation is difficult to justify with a negative P/E and no dividend yield.

Positive Factors

Revenue Growth

The company has demonstrated a significant improvement in revenue, indicating strong market demand and effective sales strategies, which are crucial for long-term growth and market expansion.

Cash Flow Improvement

Positive free cash flow suggests better cash management and operational efficiency, providing the company with more flexibility to invest in growth opportunities and reduce financial risks.

Strategic Partnerships

Strategic partnerships enhance distribution networks and product visibility, supporting long-term revenue growth and competitive positioning in the nutraceutical market.

Negative Factors

High Leverage

High financial leverage increases risk, potentially limiting the company's ability to invest in growth and manage economic downturns, impacting long-term financial stability.

Profitability Challenges

Ongoing profitability issues, despite revenue growth, highlight operational inefficiencies and the challenge of converting sales into sustainable profits, affecting long-term viability.

Negative Net Income

Consistent negative net income underscores the difficulty in achieving profitability, which can hinder reinvestment in business growth and innovation over the long term.

Healthy Extracts Business Overview & Revenue Model

Company Description

Healthy Extracts Inc., through its subsidiaries, researches, develops, and markets natural plant-based products in the United States and internationally. It offers heart health nutritional supplements; and neuro products under the KETONOMICS name that enhance brain health, including memory, cognition, focus, and neuro-energy. The company also provides bergamot products in capsule form under the BergaMet Pro+, BergaMet Mega+O, BergaMet HERHEART, BergaMet Cholesterol Command, and BergaMet SPORTSHEART products labels. It distributes bergamot products through its website and distribution sites. The company was formerly known as Grey Cloak Tech Inc. and changed its name to Healthy Extracts Inc. in October 2020. Healthy Extracts Inc. was incorporated in 2014 and is based in Littleton, Colorado.

How the Company Makes Money

Healthy Extracts makes money primarily through the sale of its nutraceutical products. The company generates revenue by selling directly to consumers through its e-commerce platform and by distributing its products through various retail and online channels. Key revenue streams include the sales of their branded supplements and custom formulations. The company also benefits from strategic partnerships with other health and wellness brands, which help expand its distribution network and increase product visibility. Additionally, Healthy Extracts may engage in licensing agreements for their proprietary formulations, providing another revenue source.

Healthy Extracts Financial Statement Overview

Summary

Revenue growth is very strong in the TTM period, and gross margin has improved to a solid level, but operating and net margins remain negative and the most recent TTM period returned to operating/FCF cash burn. Balance-sheet analysis is further limited by missing/zeroed TTM debt and equity fields, while the latest annual data indicates elevated leverage and negative returns, keeping overall financial risk high.

Income Statement

TTM (Trailing-Twelve-Months) revenue is up strongly (about +507% vs the prior period provided), but profitability remains weak with negative operating and net margins (net margin roughly -33%). While gross margin in TTM is positive (~52%) and markedly better than 2020’s negative gross margin, operating losses persist (negative EBIT/EBITDA), indicating the cost structure is still too heavy relative to the current revenue base.

Balance Sheet

Leverage looks mixed depending on the period: 2024 shows high leverage (debt-to-equity ~2.30) and negative returns on equity, reflecting continued losses and pressure on the capital base. In TTM (Trailing-Twelve-Months), reported debt and equity are both 0, which limits interpretability and raises data-quality/availability concerns; assets are shown as large versus prior years, but without equity/debt detail it’s hard to assess solvency and balance-sheet resilience.

Cash Flow

Cash generation is inconsistent: 2024 produced positive operating cash flow and free cash flow (~$0.28M), but TTM (Trailing-Twelve-Months) reverted to cash burn (operating cash flow about -$0.16M; free cash flow about -$0.18M) and free cash flow declined sharply versus the prior period provided. A positive point is that free cash flow has generally tracked net losses closely (free cash flow roughly in line with net income), but the return to negative cash flow in TTM increases funding risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.59M	3.11M	2.49M	2.25M	1.47M	1.28M
Gross Profit	1.88M	1.91M	1.62M	1.37M	695.08K	-578.44K
EBITDA	-799.72K	-183.15K	-2.24M	-910.71K	-1.88M	-2.49M
Net Income	-1.17M	-840.67K	-2.47M	-989.96K	-2.04M	-2.65M
Balance Sheet
Total Assets	26.19M	2.38M	2.64M	2.78M	3.03M	3.12M
Cash, Cash Equivalents and Short-Term Investments	189.45K	112.02K	19.44K	65.65K	222.10K	59.20K
Total Debt	0.00	941.90K	1.13M	593.52K	342.62K	177.62K
Total Liabilities	0.00	1.97M	1.68M	902.79K	558.84K	261.61K
Stockholders Equity	0.00	410.38K	954.59K	1.88M	2.47M	2.85M
Cash Flow
Free Cash Flow	-180.06K	281.97K	-415.75K	-342.95K	-997.30K	-3.49M
Operating Cash Flow	-160.76K	281.97K	-415.75K	-334.96K	-901.30K	-3.48M
Investing Cash Flow	-19.30K	0.00	0.00	-7.99K	-96.00K	-425.88K
Financing Cash Flow	269.11K	-189.39K	369.54K	239.52K	1.16M	3.83M

Healthy Extracts Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.97
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYEX, the sentiment is Neutral. The current price of 1.97 is below the 20-day moving average (MA) of 1.98, above the 50-day MA of 1.93, and below the 200-day MA of 2.17, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 51.58 is Neutral, neither overbought nor oversold. The STOCH value of 35.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HYEX.

Healthy Extracts Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CPIX	51 Neutral	$58.93M	-16.90	-13.08%	―	12.21%	69.91%
HYEX	47 Neutral	$33.74M	-6.26	-9.44%	―	19.20%	-19.98%
SCYX	45 Neutral	$30.42M	-1.35	-53.29%	―	-65.77%	38.61%
AYTU	45 Neutral	$25.22M	-0.61	-50.23%	―	-15.61%	-68.96%
RMTI	42 Neutral	$40.59M	-6.46	-16.67%	―	-23.60%	-179.33%
COSM	40 Underperform	$17.52M	-0.66	-63.82%	―	―	―